Role of biomarkers in predicting CVD risk in the setting of HIV infection?

Current Opinion in HIV and AIDS

Volumn 5, Issue 6, 2010, Pages 467-472

  Worm, Signe W ^a   Hsue, Priscilla ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Biomarkers; cardiovascular disease; HIV; risk predictions

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; INTERLEUKIN 6;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CORONARY RISK; HEART INFARCTION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HIV INFECTIONS; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 78049252684     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833f2ea6     Document Type: Review

References (54)

1. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-330.
2. Hadigan C, Meigs JB, Wilson PW, et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003; 36:909-916.
3. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004; 23:625-630.
4. Baker J, Ayenew W, Quick H, et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis 2010; 201:285-292.
5. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-1695.
6. Wilson PW. Evidence of systemic inflammation and estimation of coronary artery disease risk: a population perspective. Am J Med 2008; 121:S15-S20.
7. Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005; 112:25-31.
8. Kaptoge S, Di AE, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta analysis. Lancet 2010; 375:132-140
9. U.S. Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 151:474-482.
10. Nielsen LB, Juul K, Nordestgaard BG. Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: in vivo evidence that lipoprotein(a) may contribute to foam cell formation. Arterioscler Thromb Vasc Biol 1998; 18:641-649.
11. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipo-proteins as risk markers of myocardial infarction in 52 countries (the INTER-HEART study): a case-control study. Lancet 2008; 372:224-233.
12. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302:412-423.
13. Abeywardena MY, Leifert WR, Warnes KE, et al. Cardiovascular biology of interleukin-6. Curr Pharm Des 2009; 15:1809-1821.
14. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol 2003; 92:522-528. (Pubitemid 37013402)
15. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 2006; 166:1368-1373.
16. Tzoulaki I, Murray GD, Lee AJ, et al. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007; 115:211 9-2127.
17. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008; 5:e78.
18. Cushman M, Lemaitre RN, Kuller LH, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999; 19:493-498.
19. Smith A, Patterson C, Yarnell J, et al. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 2005; 112:3080-3087.
20. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355:2631-2639.
21. Folsom AR, Delaney JA, Lutsey PL, et al. Associations of factor VIIIc, D-dimer, and plasmin-antiplasmin with incident cardiovascular disease and all-cause mortality. Am J Hematol 2009; 84:349-353.
22. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3:1894-1904.
23. Kaptoge S, White IR, Thompson SG, et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol 2007; 166:867-879.
24. Wilkes HC, Kelleher C, Meade TW. Smoking and plasma fibrinogen. Lancet 1988; 1:307-308.
25. Woodward M, Tunstall-Pedoe H, Rumley A, Lowe GD. Does fibrinogen add to prediction of cardiovascular disease? Results from the Scottish Heart Health Extended Cohort Study. Br J Haematol 2009; 146:442-446.
26. Garza CA, Montori VM, McConnell JP, et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007; 82:159-165.
27. Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008; 101:51F-57F.
28. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375:1536-1544.
29. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90:195-203.
30. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50:2357-2368.
31. Di AE, Chowdhury R, Sarwar N, et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009; 120:2177-2187.
32. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113:2335-2362.
33. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update - consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002; 106: 388-391.
34. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005; 39: 44-54.
35. Noursadeghi M, Miller RF. Clinical value of C-reactive protein measurements in HIV-positive patients. Int J STD AIDS 2005; 16:438-441.
36. Reingold J, Wanke C, Kotler D, et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the Fat Redistribution and Metabolic Change in HIV Infection (FRAM) study. J Acquir Immune Defic Syndr 2008; 48:142-148.
37. Neuhaus J, Jacobs DRJr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
38. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51:268-273.
39. Ford ES, Greenwald JH, Richterman AG, et al. Traditional risk factors and D- dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010; 24:1509-1517.
40. Feingold KR, Krauss RM, Pang M, et al. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993; 76:1423-1427.
41. Riddler SA, Li X, Otvos J, et al. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multi-center AIDS Cohort Study. J Acquir Immune Defic Syndr 2008; 48:281-288.
42. Rose H, Hoy J, Woolley I, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008; 199:79-86.
43. Duprez DA, Kuller LH, Tracy R, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009; 207: 524-529.
44. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151:496-507.
45. Lederman MM, Kalish LA, Asmuth D, et al. 'Modeling' relationships among HIV-1 replication, immune activation and CD4+ T-cell losses using adjusted correlative analyses. AIDS 2000; 14:951-958.
46. Kuller L and SMART study group. Elevated levels of IL-6 and D-dimer are associated with an increased risk of death in patients with HIV. In: Program and Abstracts of the15th Conference on Retrovirus and Opportunistic Infections (CROI); 3-6 February 2008; Boston, Massachusetts, USA.
47. Baker J, Quick H, Hullsiek KH et al. Interleukin-6 and d-dimer levels are associated with vascular dysfunction in patients with untreated HIV infection. HIV Med 2010. [Epub ahead of print]
48. Madden E, Lee G, Kotler DP, et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS 2008; 22:707-715.
49. Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospho-lipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26:2523-2529.
50. Mansoor A, Althoff K, Gange S, et al. Elevated NT-pro-BNP levels are associated with comorbidities among HIV-infected women. AIDS Res Hum Retroviruses 2009; 25:997-1004.
51. Hsue PY, Hunt PW, Ho JE, et al. Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail 2010; 3:132-139.
52. Duprez D on behalf of the SMART study. N-terminal pro-B-type natriuretic peptide (NT-proBNP) predicts cardiovascular disease events in HIV-infected patients: results of the SMART Study. In: Program and Abstracts of the 17th Conference on Retrovirus and Opportunistic Infections (CROI); 16-19 February 2010; San Francisco, USA.
53. Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 2010; 115:161-167.
54. Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009; 119:2408-2416.